Of note, under the current ASCO/CAP guidelines, which define ER tumor staining of 1–10% as ER positive, 18.3% of women in the ERLP/HER2- group diagnosed at 46–60 years of age without a family history, were not eligible for genetic testing, while the 18.1% of women with TNBC with similar characteristics would be eligible. The gene discussed is ERBB2; the disease is neoplasm.